BioTuesdays

Tag - Joseph Pantginis

PDS Biotechnology

HCW starts PDS Biotechnology at buy; PT $7

H.C. Wainwright initiated coverage of PDS Biotechnology (NASDAQ:PDSB) with a “buy” rating and $7 price target. The stock closed at $3.05 on Nov. 4. PDS is developing anti-cancer therapeutics leveraging its proprietary...

HCW starts aTyr Pharma at buy; PT $8

H.C. Wainwright launched coverage of aTyr Pharma (NASDAQ:LIFE) with a “buy” rating and $8 price target. The stock closed at $3.73 on Nov. 4. aTyr is developing therapies leveraging resokines, naturally occurring...

HCW starts Aravive at buy; PT $18

H.C. Wainwright launched coverage of Aravive (NASDAQ:ARAV) with a “buy” rating and $18 price target. The stock closed at $6.38 on Oct. 9. The company’s lead asset is AVB-500, an anti-GAS6 selective decoy, used to...

Bionomics

HCW ups Bionomics to buy; PT to 30 cents from 3 cents

H.C. Wainwright upgraded Bionomics (ASX:BNO) to “buy” from “neutral” and raised its price target to 30c (Australian) from three cents after the company announced results of a pharmacokinetics (PK) study of the tablet...

Subscribe

Sign up to our weekly BioTuesdays newsletter.